189681-70-7

Upstream product

• 1064662-55-0 (2R)-2-{[2-(benzyloxy)-4-nitrophenoxy]melhyl}oxirane 
• 546072-97-3 (S)-(7-nitro-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol 
• 75167-86-1 2-(benzyloxy)-1-methoxy-4-nitrobenzene 
• 636-93-1 5-nitroguaiacol 
• 100-46-9 benzylamine 
• 50352-33-5 2-benzyloxy-4-nitrophenol 
• 1064662-88-9 ethyl {(3S)-3-[(benzylamino)methyl]-6-nitro-2,3-dihydro-1,4-benzodioxin-5-yl}acetate 
• 1064662-63-0 (2S)-2-(hydroxymethyl)-2,3,8,9-tetrahydro-7H-[1,4]dioxino[2,3-e]indol-8-one 
• 1064662-59-4 [(3S)-3-(hydroxymethyl)-6-nitro-2,3-dihydro-1,4-benzodioxin-5-yl]acetic acid 
• 1064662-80-1 [(3S)-3-(hydroxymethyl)-6-nitro-2,3-dihydro-1,4-benzodioxin-5-yl]acetonitrile 
• 1064662-78-7 2-benzyloxy-4-nitrophenol 

Relevant academic research and scientific papers

COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-E]INDOL-8-ONES

Processes and intermediates arc provided for the preparation of substituted aminomethyl 2,3,8,9-tctrahydiO-7H-1.4-dioxino[2.3-e]indo]-8-ones of the Formula (A) wherein the variables n, R and R3 are as described herein. Such compounds are useful, for example, as dopamine receptor agonists.

OXINDOLEDIOXANS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO

The present invention provides methods for preparing compounds having activity as dopamine autoreceptor agonists and partial agonists at the postsynaptic dopamine D2 receptor. These compounds are useful for treating dopaminergic disorders, such

Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino?2 3-E!-indol-8-ones and derivatives

The compounds of formula I: STR1 wherein R1 and R2 are, independently, hydrogen, alkyl, phenyl or benzyl; or R1 and R2, taken together, are benzylidene optionally substituted with R3 as defined below